About moleculin biotech inc - MBRX
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company. It engages in the business of growing a pipeline including phase 2 clinical programs for hard-to-treat cancers and viruses. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe in July 2015 and is headquartered in Houston, TX.
MBRX At a Glance
Moleculin Biotech, Inc.
5300 Memorial Drive
Houston, Texas 77007
| Phone | 1-713-300-5160 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -33,560,000.00 | |
| Sector | Health Technology | Employees | 17 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MBRX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.706 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.184 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.078 |
MBRX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,974,117.647 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
MBRX Liquidity
| Current Ratio | 1.413 |
| Quick Ratio | 1.413 |
| Cash Ratio | 1.295 |
MBRX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -171.878 |
| Return on Equity | -319.848 |
| Return on Total Capital | -218.418 |
| Return on Invested Capital | -311.245 |
MBRX Capital Structure
| Total Debt to Total Equity | 2.392 |
| Total Debt to Total Capital | 2.336 |
| Total Debt to Total Assets | 1.623 |
| Long-Term Debt to Equity | 1.479 |
| Long-Term Debt to Total Capital | 1.445 |